32P-Labeling Test for DNA Damage (Environmental Carcinoens/Mutaxens/Polvethyleneimine-Celulose/Din-Laver Chromatonranhv) KURT RANDERATH, M

Total Page:16

File Type:pdf, Size:1020Kb

32P-Labeling Test for DNA Damage (Environmental Carcinoens/Mutaxens/Polvethyleneimine-Celulose/Din-Laver Chromatonranhv) KURT RANDERATH, M Proc. Natd Acad. Sci. USA Vol. 78, No. 10, pp. 6126-6129, October 1981 Biochemistry 32P-Labeling test for DNA damage (environmental carcinoens/mutaxens/polvethyleneimine-celulose/din-laver chromatonranhv) KURT RANDERATH, M. VIJAYARAJ REDDY, AND RAMESH C. GUPTA Department of Pharmacology, Baylor College of Medicine, Texas Medical Center, Houston, Texas 77030 Communicated by Paul C. Zamecnik, July 6, 1981 ABSTRACT Covalent adducts formed by the reaction ofDNA MATERIALS AND METHODS withchemicalcarcinogens and mutagens maybedetected bya32P- labeling test. DNA preparations exposed to chemicals known to Materials. N-Methyl-N-nitrosourea, dimethyl sulfate, pro- bind covalently to DNA [N-methyl-N-nitrosourea, dimethyl sul- pylene oxide (Aldrich), formaldehyde (Mallinckrodt), mechlor- fate, formaldehyde, -propiolactone, propylene oxide, strepto- ethamine (a nitrogen mustard; Merck Sharp & Dohme), strep- zotocin, nitrogen mustard, and 1,3-bis(2-chloroethyl)-1-nitrosou- tozotocin (Upjohn), 1,3-bis(2-chloroethyl)-1-nitrosourea (Bristol rea] were digested to a mixture ofdeoxynucleoside 3'-monophos- Laboratories), and (3-propiolactone (Sigma) were used without phates by incubation with micrococcal endonuclease (EC 3.1.31.1) further purification. Deoxynucleotides were from P-L Bio- and spleen exonuclease (EC 3.1.16.1). The digests were treated chemicals. [-32P]ATP was from Amersham, T4 polynucleotide with [V-3PJATP and T4 polynucleotide kinase (ATP:5'-dephos- kinase (ATP:5'-dephosphopolynucleotide 5'-phosphotransfer- phopolynucleotide 5'-phosphotransferase, EC 2.7.1.78) to convert ase, EC 2.7.1.78) was from P-L Biochemicals, and potato apyr- the monophosphates to 5'-32P-labeled deoxynucleoside 3',5'-bis- ase (ATP diphosphohydrolase, EC 3.6.1.5; grade I, 0.002 unit/ phosphates. These compounds were then separated on polyethyl- Ag) was from Sigma. Micrococcal endonuclease (EC 3.1.31.1; eneimine-cellulose thin layers in ammonium formate and am- grade VI, 0.21 unit/pkg; Sigma) and spleen exonuclease (EC monium sulfate solutions. Autoradiograms of the chromatograms 3.1.16.1; 0.002 unit/pg; Boehnnger Mannheim) were dialyzed obtained by this high-resolution procedure showed the presence against water at 40C for 15 hr. Calf thymus DNA was obtained ofnucleotides derived from chemically altered, as well as normal, DNA constituents. Maps firom DNA exposed to any of the chem- from Sigma. Polyethyleneimine (PEI)-cellulose thin layers (25 icals used exhibited a spot pattern typical for the particular chem- cm x 20 cm), prepared as described (14), were predeveloped ical. This method detected a single adduct in 105 DNA nucleotides in water for 12-15 hr (14) prior to use. XAR-5 films (Eastman without requiring that the compound under investigation be ra- Kodak) and Lightning Plus intensifying screens (Du Pont) were dioactive and thus provides a useful test to screen chemicals for used for autoradiography. DNA concentration was estimated their capacity to damage DNA by covalent binding. spectrophotometrically at neutral pH using 20 ANO units/mg for native DNA as standard (15). As shown by the Salmonella test established by Ames and co- Alkylation of DNA. Calf thymus DNA (25 jug) was allowed workers (1, 2) and by other tests (3-6), most carcinogens are to react with various chemicals as specified in Table 1. The either mutagens (i.e., electrophilic reactants that covalently treated DNA was purified by precipitation with alcohol (2.5 vol) bind to DNA bases) or premutagens (i.e., chemicals that at pH 5.0 or dialysis (40C, 15 hr) as indicated in Table 1. Control undergo metabolic conversion to such electrophilic compounds) incubations were performed in the absence of test chemicals. (7-10). Damage to DNA by chemicals is likely to be a major Digestion, 32P Labeling, and Mapping of Labeled Digests. cause ofcancer (2, 7, 8) and may also play a role in otherdiseases Treated or control DNA was quantitatively digested to deoxy- (2). It is therefore important to identify DNA-reactive chemicals nucleoside 3'-monophosphates by incubating 1 jug of DNA in the human environment. Surprisingly, no sensitive and gen- (=3 nmol of DNA-P) at 37°C for 2 hr with 2 ,ug each of micro- erally applicable test has been developed to detect directly the coccal endonuclease and spleen exonuclease in 10 p1 of20 mM presence of chemically altered bases in DNA. Most assays are sodium succinate/8 mM CaCl2, pH 6.0. For 32P labeling, the for the binding ofradioactively labeled or fluorescent test com- digest was diluted 1:10 and a 1-,ul aliquot containing %30 pmol pounds to DNA and are thus not generally applicable to screen- of deoxynucleoside 3'-monophosphates was added to 10 pA of ing large numbers of chemicals (4). A method for the analysis 10 p.M [Y-32P]ATP (100 Ci/mmol; 1 Ci = 3.7 X 10'0becquerels)/ of nonradioactive modified constituents in RNA that involves 40 mM N,N-bis(2-hydroxyethyl)glycine-NaOH, pH 9.0/10 mM digestion ofthe RNA to monomers, incorporation ofradioactive MgClJ/1o mM dithiothreitoV0. 1 mM spermidine/T4 polynu- label into the latter, thin-layer chromatography, autoradio- cleotide kinase (0.25 unit/1A). Incubation was at 37C for 1 hr. graphy or fluorography, and assay for radioactivity has been The 32P-labeled reaction mixture was further incubated with 3 reported (11). We have recently developed aformally analogous Al of apyrase (5 milliunits/jl) at 370C for 30 min to convert method for the quantitative analysis of normal DNA constitu- unreacted [y32P]ATP to 3'Pi. Three microliters of0.2 M sodium ents (12). Here we report an extension ofthis method to detect tungstate was added to the reaction mixture. Then, 1 p.1 of a the presence oftraces ofchemically altered constituents in DNA mixture ofauthentic dpGp, dpAp, dpCp, and dpTp (2 pLg each) damaged by mutagens. Part of this work has been communi- and 2 p1 ofthe reaction mixture (3.5 pmol of[32P]deoxynucleoside in form 3',5'-bisphosphates) were applied to a PEI-cellulose sheet 1.5 cated preliminary (13). cm from the lower edge and 2.5 cm from the left-hand edge. was with water to the then The publication costs ofthis article were defrayed in part bypage charge The chromatogram developed origin, payment. This article must therefore be hereby marked "advertise- ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. Abbreviation: PEI, polyethyleneimine. 6126 Biochemistry: Randerath et aL Proc. Natd Acad. Sci. USA 78 (1981) 6127 Table 1. Conditions for DNA treatment ..f Incu- DNA Concen- bation purifi- tration, DNA-P, time at cation Mutagen mM mM Buffer* 370C, hr methodt None (control) 0 0.6 A 2 P N-Methyl-N- nitrosourea 80 3 A 2 P a. Control b. N-Methyl-N- c. Dimethyl sulfate Dimethyl sulfate 45 1 A 0.5 D nOirOsUrre Formaldehydet 370 1.5 B 4 D ,&Propiolactone 260 3 A 12 P Propylene oxide 200 3 C 12 P Streptozotocin 40 0.6 A 1.5 P Nitrogen mustard§ 43 0.6 B 5 D 1,3-Bis- (2-chloroethyl)- 1-nitrosourea 40 0.6 A 1.5 P * A, 0.2 M Tris HCl, pH 8.0; B, 0.2 M K phosphate, pH 8.5; C, 1.5 M NaOAc, pH 5.8. d. Formaldehyde e. 0- tP, alcohol precipitation; D, dialysis. t DNA was denatured by heating at 1000C for 10 min before exposure to formaldehyde. § This chemical contained NaCl (concentration in the reaction mix- ture, 1.1 M). with 4 M lithium formate/7.5 M urea, pH 4.0 (prepared by ti- tration of a formic acid/urea mixture with lithium hydroxide) to 5 cm above the origin. The sheet was soaked in 300 ml of methanol for 10 min, dried in a current of cool air, and cut 1 cm above the origin. The lower part, containing mainly 32P, (retained at the origin as a tungstate complex), was discarded. g. Streptozotocin h. Nitrogen i. ,'3-Bis(2-chloro- The upper portion was developed with 0.04 M ammonium for- mustard eff)yO-I-nitrosourea mate, pH 3.5 (prepared by titration of formic acid with am- monium hydroxide) to 3 cm from the cut edge, then, without intermediate with 0.7 M FIG. 1. Pmaps ofdigestsofcontrolcalfthymusDNA(a)andcalf drying, ammonium formate, pH 3.5, thymus DNA treated with the indicated electrophilic chemical (b-i). to 6 cm on a Whatman 1 wick that had been attached 21-22 cm DNA samples were digested to deoxynucleoside 3'-monophosphates, from the bottom edge by stapling and folded back. After chro- which were 32P labeled, and the resulting 3',5'-bisphosphates were matography, the layer was dried in a current ofcool air followed mapped on PEI-cellulose thin layers. [y.32P]ATP had a specific activity by warm air (5 min each). The sheet was soaked in 300 ml of0.01 of 100 Ci/mmol. The labeled DNA digests [total radioactivity, 1.2 AuCi; M Tris base in water for 10 min, then in 300 ml of water for 5 3.5 pmol (0.35 MCi) of [32P]deoxynucleoside 3',5'-bisphosphates] were min and dried. in the second chromatographed on anion-exchange thin-layer sheets of PEI-cellu- Chromatography dimension was lose in formate (bottom to top) and sulfate (leftto right) solutions. Auto- performed with 0.01 M Tris HCl, pH 8.0, to the origin, then radiography was at -70°C for 7-9 hr, except for samples a and i, which with 0.1 M ammonium sulfate/0.01 M Tris HCl, pH 8.0, to 7 were exposed for 12 and 16 hr, respectively. Spots of dpGp (G), dpAp cm on a Whatman 1 wick attached to the top ofthe sheet.
Recommended publications
  • Carcinogen-Induced Early Molecular Events and Its Implication In
    Biochimica et Biophysica Acta 1772 (2007) 48–59 www.elsevier.com/locate/bbadis Carcinogen-induced early molecular events and its implication in the initiation of chemical hepatocarcinogenesis in rats: Chemopreventive role of vanadium on this process Tridib Chakraborty a, Amrita Chatterjee a, Ajay Rana b, Duraisami Dhachinamoorthi a, ⁎ Ashok Kumar P a, Malay Chatterjee a, a Division of Biochemistry, Department of Pharmaceutical Technology, Jadavpur University, PO Box 17028, Calcutta-700032, India b Division of Molecular Cardiology, Cardiovascular Research Institute, College of Medicine, The Texas A&M University System HSC, Temple, TX 76504, USA Received 21 May 2006; received in revised form 19 September 2006; accepted 16 October 2006 Available online 10 November 2006 Abstract Carcinogen-induced formation of DNA adducts and other types of DNA lesions are the critical molecular events in the initiation of chemical carcinogenesis and modulation of such events by chemopreventive agents could be an important step in limiting neoplastic transformation in vivo. Vanadium, a dietary micronutrient has been found to be effective in several types of cancers both in vivo and in vitro and also possesses profound anticarcinogenicity against rat models of mammary, colon and hepatocarcinogenesis. Presently, we report the chemopreventive potential of vanadium on diethylnitrosamine (DEN)-induced early DNA damages in rat liver. Hepatocarcinogenesis was induced in male Sprague–Dawley rats with a single, necrogenic, intraperitoneal (i.p.) injection of DEN (200 mg/kg body weight) at week 4. There was a significant induction of tissue- specific ethylguanines, steady elevation of modified DNA bases 8-hydroxy-2′-deoxyguanosines (8-OHdGs) (P<0.0001; 89.93%) along with substantial increment of the extent of single-strand breaks (SSBs) (P<0.0001) following DEN exposure.
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]
  • Manual D'estil Per a Les Ciències De Laboratori Clínic
    MANUAL D’ESTIL PER A LES CIÈNCIES DE LABORATORI CLÍNIC Segona edició Preparada per: XAVIER FUENTES I ARDERIU JAUME MIRÓ I BALAGUÉ JOAN NICOLAU I COSTA Barcelona, 14 d’octubre de 2011 1 Índex Pròleg Introducció 1 Criteris generals de redacció 1.1 Llenguatge no discriminatori per raó de sexe 1.2 Llenguatge no discriminatori per raó de titulació o d’àmbit professional 1.3 Llenguatge no discriminatori per raó d'ètnia 2 Criteris gramaticals 2.1 Criteris sintàctics 2.1.1 Les conjuncions 2.2 Criteris morfològics 2.2.1 Els articles 2.2.2 Els pronoms 2.2.3 Els noms comuns 2.2.4 Els noms propis 2.2.4.1 Els antropònims 2.2.4.2 Els noms de les espècies biològiques 2.2.4.3 Els topònims 2.2.4.4 Les marques registrades i els noms comercials 2.2.5 Els adjectius 2.2.6 El nombre 2.2.7 El gènere 2.2.8 Els verbs 2.2.8.1 Les formes perifràstiques 2.2.8.2 L’ús dels infinitius ser i ésser 2.2.8.3 Els verbs fer, realitzar i efectuar 2.2.8.4 Les formes i l’ús del gerundi 2.2.8.5 L'ús del verb haver 2.2.8.6 Els verbs haver i caldre 2.2.8.7 La forma es i se davant dels verbs 2.2.9 Els adverbis 2.2.10 Les locucions 2.2.11 Les preposicions 2.2.12 Els prefixos 2.2.13 Els sufixos 2.2.14 Els signes de puntuació i altres signes ortogràfics auxiliars 2.2.14.1 La coma 2.2.14.2 El punt i coma 2.2.14.3 El punt 2.2.14.4 Els dos punts 2.2.14.5 Els punts suspensius 2.2.14.6 El guionet 2.2.14.7 El guió 2.2.14.8 El punt i guió 2.2.14.9 L’apòstrof 2.2.14.10 L’interrogant 2 2.2.14.11 L’exclamació 2.2.14.12 Les cometes 2.2.14.13 Els parèntesis 2.2.14.14 Els claudàtors 2.2.14.15
    [Show full text]
  • Mimicking the Action of Ribonucleases: Studies on Rnase a and Design of PNA Based Artificial Enzymes
    From DEPARTMENT OF BIOSCIENCES AND NUTRITION Karolinska Institutet, Stockholm, Sweden Mimicking the action of ribonucleases: studies on RNase A and design of PNA based artificial enzymes Alice Ghidini Stockholm 2015 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Eprint AB 2015 © Alice Ghidini, 2015 ISBN 978-91-7676-039-0 Mimicking the action of ribonucleases: studies on RNase A and design of PNA based artificial enzymes THESIS FOR DOCTORAL DEGREE (Ph.D.) By Alice Ghidini Principal Supervisor: Opponent: Professor Roger Strömberg Professor Michael J. Gait Karolinska Institutet Medical Research Council Department of Bioscience and nutrition Department of Laboratory of Molecular Biology Division of Bioorganic chemistry Examination Board: Co-supervisor(s): Lars Baltzer Merita Murtola Uppsala Universitet Karolinska Institutet Department of Institutionen för kemi Department of Bioscience and nutrition Division of BMC, Fysikalisk organisk kemi Division of Bioorganic chemistry Mikael Leijon Malgorzata Honcharenko National Veterinary Institute (SVA) Karolinska Institutet Division of Virology, Immunobiology and Department of Bioscience and nutrition Parasitology (VIP) Division of Bioorganic chemistry Marcus Wilhelmsson Chalmers University of Technology Department of Chemical and Chemical Engineering/Chemistry and Biochemistry With love to my family, lontani ma sempre vicini… ABSTRACT A 3’-deoxy-3’-C-methylenephosphonate modified diribonucleotide is highly resistant to degradation by spleen phosphodiesterase and not cleaved at all by snake venom phosphodiesterase. Despite that both the vicinal 2-hydroxy nucleophile and the 5’-oxyanion leaving group are intact, the 3’-methylenephosponate RNA modification is also highly resistant towards the action of RNase A. Several different approaches were explored for conjugation of oligoethers to PNA with internally or N-terminal placed diaminopropionic acid residues.
    [Show full text]
  • Sequence Verification of Oligonucleotides Containing Multiple Arylamine Modifications by Enzymatic Digestion and Liquid Chromatography Mass Spectrometry (LC/MS)
    Sequence Verification of Oligonucleotides Containing Multiple Arylamine Modifications by Enzymatic Digestion and Liquid Chromatography Mass Spectrometry (LC/MS) Lan Gao,a Li Zhang,b Bongsup P. Cho,b and M. Paul Chiarellia a Department of Chemistry, Loyola University, Chicago, Illinois, USA b Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA An©analytical©method©for©the©structure©differentiation©of©arylamine©modified©oligonucleotides (ODNs)©using©on-line©LC/MS©analysis©of©raw©exonuclease©digests©is©described.©Six©different dodeca©ODNs©derived©from©the©reaction©of©N-acetoxy-N-(trifluoroacetyl)-2-aminofluorene with©the©dodeca©oligonucleotide©5=-CTCGGCGCCATC-3=©are©isolated©and©sequenced©with©this LC/MS©method©using©3=-©and©5=-exonucleases.©When©the©three©products©modified©by©a©single aminofluorene©(AF)©are©subjected©to©3=-exonuclease©digestion,©the©exonuclease©will©cleave©a modified©nucleotide©but©when©di-AF©modified©ODNs©are©analyzed©the©3=-exonuclease©ceases to©cleave©nucleotides©when©the©first©modification©is©exposed©at©the©3=-terminus.©Small abundances©of©ODN©fragments©formed©by©the©cleavage©of©an©AF-modified©nucleotide©were observed©when©two©of©the©three©di-AF©modified©ODNs©were©subjected©to©5=-exonuclease digestion.©The©results©of©the©5=-exonuclease©studies©of©the©three©di-AF©modified©ODNs©suggest that©as©the©number©of©unmodified©bases©between©two©modifications©in©an©ODN©sequence increases,©the©easier©it©becomes©to©sequence©beyond©the©modification©closest©to©the©5©=-terminus. The©results©of©this©study©indicate©that©the©LC/MS©method©described©here©would©be©useful©in sequencing©ODNs©modified©by©multiple©arylamines©to©be©used©as©templates©for©site-specific mutagenesis©studies.© (J©Am©Soc©Mass©Spectrom©2008,©19,©1147–1155)©©©2008©American©Society for©Mass©Spectrometry nterest©in©the©analysis©of©carcinogen-modified©nu- depend©on©the©number©of©guanine©bases©present©in©the cleic©acids©is©motivated©by©the©belief©that©the©forma- sequence.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii
    POLSKIE TOWARZYSTWO BIOCHEMICZNE Postępy Biochemii http://rcin.org.pl WSKAZÓWKI DLA AUTORÓW Kwartalnik „Postępy Biochemii” publikuje artykuły monograficzne omawiające wąskie tematy, oraz artykuły przeglądowe referujące szersze zagadnienia z biochemii i nauk pokrewnych. Artykuły pierwszego typu winny w sposób syntetyczny omawiać wybrany temat na podstawie możliwie pełnego piśmiennictwa z kilku ostatnich lat, a artykuły drugiego typu na podstawie piśmiennictwa z ostatnich dwu lat. Objętość takich artykułów nie powinna przekraczać 25 stron maszynopisu (nie licząc ilustracji i piśmiennictwa). Kwartalnik publikuje także artykuły typu minireviews, do 10 stron maszynopisu, z dziedziny zainteresowań autora, opracowane na podstawie najnow­ szego piśmiennictwa, wystarczającego dla zilustrowania problemu. Ponadto kwartalnik publikuje krótkie noty, do 5 stron maszynopisu, informujące o nowych, interesujących osiągnięciach biochemii i nauk pokrewnych, oraz noty przybliżające historię badań w zakresie różnych dziedzin biochemii. Przekazanie artykułu do Redakcji jest równoznaczne z oświadczeniem, że nadesłana praca nie była i nie będzie publikowana w innym czasopiśmie, jeżeli zostanie ogłoszona w „Postępach Biochemii”. Autorzy artykułu odpowiadają za prawidłowość i ścisłość podanych informacji. Autorów obowiązuje korekta autorska. Koszty zmian tekstu w korekcie (poza poprawieniem błędów drukarskich) ponoszą autorzy. Artykuły honoruje się według obowiązujących stawek. Autorzy otrzymują bezpłatnie 25 odbitek swego artykułu; zamówienia na dodatkowe odbitki (płatne) należy zgłosić pisemnie odsyłając pracę po korekcie autorskiej. Redakcja prosi autorów o przestrzeganie następujących wskazówek: Forma maszynopisu: maszynopis pracy i wszelkie załączniki należy nadsyłać w dwu egzem­ plarzach. Maszynopis powinien być napisany jednostronnie, z podwójną interlinią, z marginesem ok. 4 cm po lewej i ok. 1 cm po prawej stronie; nie może zawierać więcej niż 60 znaków w jednym wierszu nie więcej niż 30 wierszy na stronie zgodnie z Normą Polską.
    [Show full text]
  • Nucleic Acid Therapeutics Applications Notebook Table of Contents
    Nucleic acid therapeutics applications notebook Table of Contents Introduction .....................................................................................................................................................................................3 Analysis of Nucleic Acids ................................................................................................................................................................5 Analysis of Phosphorothioate Oligonucleotides ...............................................................................................................................6 Analysis of ss- and dsRNA ...............................................................................................................................................................8 Anion-Exchange ESI/MS of Oligonucleotides—Analysis of Impurities in the Target Oligonucleotide Product .......................12 Anion-Exchange ESI/MS of Oligonucleotides—Analysis of Oxidation Products of Purified Biotinylated Oligonucleotides ..................................................................................................................................15 Analysis of 2´, 5´-Linkage Isomers in RNA and DNA, and Elucidation of Aberrant Linkage Position ......................................17 Analysis of Nucleoside Mono-, Di-, and Triphosphates ................................................................................................................22 Method Development Using Anion-Exchange Chromatography for Nucleic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Amfep Guidance on REACH Pre-Registration of Enzymes
    Amfep/08/44 30 May 2008 Amfep guidance on REACH pre-registration of enzymes 1. Purpose and timing During the period 1 June to 1 December 2008, European enzyme manufacturers and importers can pre-register the enzyme substances currently manufactured in EU and imported into the EU for technical applications. Manufacturers and importers inside the EU may appoint Third Party Representatives to remain anonymous and if based outside the EU, they may appoint Only Representatives. The pre-registration provision of REACH enables substances to remain on the market subject to later registration in 2010, 2013 or 2018, depending on tonnage. Pre-registration is made to the European Chemicals Agency (ECHA) and result in the formation of a Substance Information Exchange Forum (SIEF) per enzyme. ECHA will publish a list of pre- registered substances by 1 January 2009. Amfep has formed a pre-consortium of members and associated manufacturing companies to prepare enzyme (pre-) registrations and SIEF discussions. The Amfep secretariat can be contacted for further information and on questions related to enzyme pre-registrations. This document is intended to facilitate pre-registration of enzymes. References are given to detailed guidance on enzyme identification, pre-registration and other REACH requirements. However, it must be considered as guidance only. Each potential registrant remains fully responsible for selecting its enzymes and making individual pre-registrations. 2. Scope Enzymes listed on the European chemicals inventory EINECS are considered phase-in (‘existing’) substances and can be pre-registered. Enzymes manufactured in the EU at least once after 31 May 1992, without being placed on the EU market by the manufacturer or importer, are regarded as phase-in substances.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]